Cargando…

Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database

BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare but aggressive malignant disease in the lung. It is characterized by coexisting histologic elements of carcinomatous and sarcomatous components. This study aimed to comprehensively understand the clinical features of PCS and develop a nomogram for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ming-Yi, Tang, Lian-Sha, Qin, Zhao-Juan, Hao, Ya-Ting, Cheng, Ke, Zheng, Ai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622765/
https://www.ncbi.nlm.nih.gov/pubmed/36330063
http://dx.doi.org/10.3389/fmed.2022.988830
_version_ 1784821846635446272
author Zhang, Ming-Yi
Tang, Lian-Sha
Qin, Zhao-Juan
Hao, Ya-Ting
Cheng, Ke
Zheng, Ai
author_facet Zhang, Ming-Yi
Tang, Lian-Sha
Qin, Zhao-Juan
Hao, Ya-Ting
Cheng, Ke
Zheng, Ai
author_sort Zhang, Ming-Yi
collection PubMed
description BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare but aggressive malignant disease in the lung. It is characterized by coexisting histologic elements of carcinomatous and sarcomatous components. This study aimed to comprehensively understand the clinical features of PCS and develop a nomogram for prognostic prediction of PCS patients. METHODS: Data were collected from the Surveillance Epidemiology and End Results (SEER) database between 1975 and 2018. Propensity-score matching (PSM) was used to match the demographic characteristic of the PCS vs. pulmonary sarcoma (PS). Cancer-specific survival (CSS) and overall survival (OS) were the main endpoints of the survival of patients and were evaluated using the Kaplan Meier curves and Cox proportional hazards regression. We further randomly split enrolled PCS patients from SEER into the training and validation sets. All independent predictors for OS of the training set were integrated to create a predictive nomogram. The performance of the nomogram was determined by discrimination, calibration ability, clinical usefulness, and risk stratification ability both in the training and validation cohorts. In addition, the clinical data of PCS patients from the West China Hospital were also retrospectively analyzed by this model. RESULTS: A total of 428 PCS patients and 249 PS patients were enrolled from SEER. Compared to pure PS, PCS was associated with significantly better survival in the unmatched cohorts, whereas non-significantly better survival after PSM. In subgroup analysis, PCS showed significantly worse survival than pure PS in subgroups among the race, marital status, and radiation treatment. A nomogram was constructed for PCS patients’ survival prediction by combining the independent risk factors, including gender, stage, surgery, radiation, and chemotherapy. The nomogram showed good discrimination, calibration, and predictive power in the training and validation sets. Risk stratification analysis indicated that the nomogram scores efficiently divided PCS patients into low and high-risk groups. CONCLUSION: PCS is a rare malignant disease of the lung with distinct clinical features. It had a comparable survival compared with pure PS in the matched cohorts. In addition, a nomogram was developed and validated for predicting the OS in PCS patients.
format Online
Article
Text
id pubmed-9622765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96227652022-11-02 Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database Zhang, Ming-Yi Tang, Lian-Sha Qin, Zhao-Juan Hao, Ya-Ting Cheng, Ke Zheng, Ai Front Med (Lausanne) Medicine BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare but aggressive malignant disease in the lung. It is characterized by coexisting histologic elements of carcinomatous and sarcomatous components. This study aimed to comprehensively understand the clinical features of PCS and develop a nomogram for prognostic prediction of PCS patients. METHODS: Data were collected from the Surveillance Epidemiology and End Results (SEER) database between 1975 and 2018. Propensity-score matching (PSM) was used to match the demographic characteristic of the PCS vs. pulmonary sarcoma (PS). Cancer-specific survival (CSS) and overall survival (OS) were the main endpoints of the survival of patients and were evaluated using the Kaplan Meier curves and Cox proportional hazards regression. We further randomly split enrolled PCS patients from SEER into the training and validation sets. All independent predictors for OS of the training set were integrated to create a predictive nomogram. The performance of the nomogram was determined by discrimination, calibration ability, clinical usefulness, and risk stratification ability both in the training and validation cohorts. In addition, the clinical data of PCS patients from the West China Hospital were also retrospectively analyzed by this model. RESULTS: A total of 428 PCS patients and 249 PS patients were enrolled from SEER. Compared to pure PS, PCS was associated with significantly better survival in the unmatched cohorts, whereas non-significantly better survival after PSM. In subgroup analysis, PCS showed significantly worse survival than pure PS in subgroups among the race, marital status, and radiation treatment. A nomogram was constructed for PCS patients’ survival prediction by combining the independent risk factors, including gender, stage, surgery, radiation, and chemotherapy. The nomogram showed good discrimination, calibration, and predictive power in the training and validation sets. Risk stratification analysis indicated that the nomogram scores efficiently divided PCS patients into low and high-risk groups. CONCLUSION: PCS is a rare malignant disease of the lung with distinct clinical features. It had a comparable survival compared with pure PS in the matched cohorts. In addition, a nomogram was developed and validated for predicting the OS in PCS patients. Frontiers Media S.A. 2022-10-18 /pmc/articles/PMC9622765/ /pubmed/36330063 http://dx.doi.org/10.3389/fmed.2022.988830 Text en Copyright © 2022 Zhang, Tang, Qin, Hao, Cheng and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zhang, Ming-Yi
Tang, Lian-Sha
Qin, Zhao-Juan
Hao, Ya-Ting
Cheng, Ke
Zheng, Ai
Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database
title Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database
title_full Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database
title_fullStr Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database
title_full_unstemmed Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database
title_short Clinical features and prognostic factors of pulmonary carcinosarcoma: A nomogram development and validation based on surveillance epidemiology and end results database
title_sort clinical features and prognostic factors of pulmonary carcinosarcoma: a nomogram development and validation based on surveillance epidemiology and end results database
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622765/
https://www.ncbi.nlm.nih.gov/pubmed/36330063
http://dx.doi.org/10.3389/fmed.2022.988830
work_keys_str_mv AT zhangmingyi clinicalfeaturesandprognosticfactorsofpulmonarycarcinosarcomaanomogramdevelopmentandvalidationbasedonsurveillanceepidemiologyandendresultsdatabase
AT tangliansha clinicalfeaturesandprognosticfactorsofpulmonarycarcinosarcomaanomogramdevelopmentandvalidationbasedonsurveillanceepidemiologyandendresultsdatabase
AT qinzhaojuan clinicalfeaturesandprognosticfactorsofpulmonarycarcinosarcomaanomogramdevelopmentandvalidationbasedonsurveillanceepidemiologyandendresultsdatabase
AT haoyating clinicalfeaturesandprognosticfactorsofpulmonarycarcinosarcomaanomogramdevelopmentandvalidationbasedonsurveillanceepidemiologyandendresultsdatabase
AT chengke clinicalfeaturesandprognosticfactorsofpulmonarycarcinosarcomaanomogramdevelopmentandvalidationbasedonsurveillanceepidemiologyandendresultsdatabase
AT zhengai clinicalfeaturesandprognosticfactorsofpulmonarycarcinosarcomaanomogramdevelopmentandvalidationbasedonsurveillanceepidemiologyandendresultsdatabase